Jordi Gracia

Dr. Jordi Gracia

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2026 in Molecules
Verified
Journal Article
Open access
PDF file
CVClaudia Vergelli
Claudia Vergelli
Letizia CrocettiLetizia Crocetti
Letizia Crocetti
GGGabriella GUERRINI
Gabriella GUERRINI
FMFabrizio Melani
Fabrizio Melani
JGJordi Gracia
Jordi Gracia
MGMaria P. Giovannoni
Maria P. Giovannoni
Phospodiesterase 4 (PDE4) has long been an attractive target not only for the anti-inflammatory therapy in respiratory diseases, but also for other pathologies such as psoriatic arthritis and atopic dermatitis. In this study, we report the synthesis of 5-acetyl-2-ethyl-6-phenyl-3(2H)-pyridazinones differently substituted at position 4 with a variety of aryl/alkylamines, which act as potent PDE4B1 inhibitors in the low nanomolar range. The selectivity toward PDE4A4, PDE4D3 and HARBS, as well as the ability to inhibit TNFα production in human whole blood (hWB), was also evaluated for the most potent products, resulting in a small cluster of compounds with an interesting profile and two selected products (3a and 3k) have been in depth investigated with additional in vitro tests on metabolism and in vivo studies. Finally, molecular docking and minimization of the ligand-enzyme complexes were carried out.